Sanofi India Limited
All news and filings related to Sanofi India Limited.
View all news & filings- Medium impact
Supreme Court dismisses Sanofi India's plea to quash criminal proceedings
The Supreme Court dismissed Sanofi India's petition to quash criminal proceedings related to alleged conspiracy in procurement decisions. The company is assessing the judgment and its next litigation strategy. No penalty or operational restriction has been imposed at this stage.
Read the summary - Medium impact
Sanofi India Receives GST Show Cause Notice for ₹72.77 Crore Tax and Penalty
Sanofi India received a GST Show Cause Notice alleging product misclassification for FY 2020-21. The notice proposes a tax liability of ₹36.39 crore and a penalty of ₹36.39 crore, totaling ₹72.77 crore. The company is consulting advisors and expects no adverse financial impact.
Read the summary - Medium impact
Sanofi India Q2 2026: Diabetes Business Drives 14% Growth, PBT Up 19%
Sanofi India reported a strong Q2 2026 with its diabetes business driving 14% growth. Profit Before Tax (PBT) increased by 19% to ₹112 crore. The company continues to lead in the basal analog insulin market. Management is working to improve partnership business growth, expecting a return to industry-led growth by 2027. CSR initiatives are ahead of schedule.
Read the summary - Low impact
Sanofi India Ltd Shares Video Recording of Investor Call on Q2 2026 Results
Sanofi India Limited has uploaded the video recording of its Investor/Analysts Call held on August 5, 2026. The call provided updates on the unaudited financial results for the quarter and half-year ended June 30, 2026. The recording is available on the company's website.
Read the summary - Medium impact
Sanofi India Q1 FY27 Results: Revenue at ₹312.74 Crore, Net Profit at ₹45.14 Crore
Sanofi India reported Q1 FY27 results with total income from operations at ₹312.74 crore, down from ₹331.06 crore YoY. Net profit after tax rose to ₹45.14 crore from ₹41.57 crore. For the half-year, income was ₹643.80 crore and net profit was ₹86.71 crore. Basic EPS was ₹1.36.
Read the summary - Medium impact
Sanofi India Limited H1'26: Diabetes Business Grows 17%, Q2 Profit Before Tax Up 19%
Sanofi India Limited reported strong Q2 2026 results with net sales up 8% to ₹9,542 million. The diabetes business, a key focus, grew 17% in H1 2026. Profit before tax in Q2 2026 increased by 19% to ₹1,123 million, driven by business performance and operational efficiencies. The company is leveraging its innovative portfolio and partnerships to drive growth.
Read the summary - Medium impact
Sanofi India Q2 FY26: Profit Before Tax Up 19% to ₹112 Crore, Revenue Grows 6%
Sanofi India reported Q2 FY26 results with total net sales up 6% to ₹437.7 crore. Profit before tax grew 19% to ₹112 crore. The insulin portfolio saw 14% growth. Committees were re-constituted effective October 1, 2026.
Read the summary - Medium impact
Sanofi India Q2 FY26 Profit Up 19% to ₹112 Crore on Strong Diabetes Portfolio
Sanofi India reported Q2 FY26 profit before tax of ₹112 crore, a 19% increase year-on-year. Domestic net sales grew 8%, and total net sales grew 6%. The insulin portfolio saw 14% growth. The Board approved these results and re-constituted committees effective October 1, 2026, following Mr. Rachid Ayari's cessation as CFO on September 30, 2026.
Read the summary - Low impact
Sanofi India Announces Change in Senior Management Personnel
Mr. Nakul Verma, Head of Public Affairs & Market Access at Sanofi India, will cease to be Senior Management Personnel effective July 31, 2026. This change is due to his transition to another role within the Sanofi group.
Read the summary - Low impact
Sanofi India to hold Investor/Analyst Call on Aug 5th for Q2 2026 Results Update
Sanofi India Limited will hold an investor and analyst call on August 5, 2026, to discuss unaudited financial results for the quarter and half-year ended June 30, 2026. The call is from 4:00 PM to 5:00 PM IST. Pre-registration is required.
Read the summary - Medium impact
Sanofi India's CFO Rachid Ayari Resigns, Effective Sept 30, 2026
Rachid Ayari will step down as Whole Time Director, CFO, and KMP of Sanofi India Limited. His resignation is effective September 30, 2026, as he transitions to a new role within the Sanofi group. The company is seeking a replacement.
Read the summary - Medium impact
Sanofi India's CFO Rachid Ayari Resigns Effective September 30, 2026
Mr. Rachid Ayari will step down as Whole Time Director, CFO, and KMP of Sanofi India Limited. His resignation is effective September 30, 2026, due to a transition within the Sanofi group. The company is seeking a replacement.
Read the summary - Medium impact
Sanofi India CFO Rachid Ayari Resigns Effective September 30
Rachid Ayari will step down as Whole Time Director, CFO, and KMP of Sanofi India on September 30, 2026, to take another role within the Sanofi group. The company is seeking a replacement.
Read the summary - Medium impact
Sanofi India CFO Rachid Ayari to Resign on Sept 30, 2026
Rachid Ayari will resign as Whole Time Director, CFO, and KMP of Sanofi India Limited effective September 30, 2026. He is transitioning to another role within the Sanofi group. The company is seeking a replacement.
Read the summary - Low impact
Sanofi India Limited Wins Income Tax Appeal, Rs. 72.7 Lakh Demand Deleted
Sanofi India Limited received a favourable order from the Income Tax Appellate Authority, deleting a demand of ₹72.71 lakh for Assessment Year 2019-20. The appeal pertained to non-deduction of taxes on year-end provisions. The company confirmed no material impact on its financials or operations.
Read the summary - Low impact
Sanofi India Trading Window Closed for Q2 2026 Results
Sanofi India Limited will close its trading window from July 1, 2026, for designated persons. This is to facilitate the declaration of unaudited financial results for the quarter and half year ending June 30, 2026. The window will reopen 48 hours after the results announcement.
Read the summary - Low impact
Sanofi India Appoints Mr. Debajit Roy as Sales & Customer Engagement Head – Diabetes
Sanofi India Limited appointed Mr. Debajit Roy as Sales & Customer Engagement Head – Diabetes, effective June 8, 2026. Mr. Roy, a business leader with over 20 years of experience, holds an MBA and a B.Sc. This appointment was approved by the Board on June 3, 2026.
Read the summary - Low impact
Sanofi India Limited: Kerala Tax Authority Drops Proceedings for FY 2020-21
Sanofi India Limited received an acceptance order from Kerala Tax Authority dropping proceedings for FY 2020-21. The order relates to discrepancies in e-way bills and input tax credit, with a scrutiny amount of ₹59,77,141. The company confirms no material financial or operational impact.
Read the summary - Low impact
Sanofi India Limited Announces Special Window for Share Transfer and Dematerialisation
Sanofi India Limited announced a special window for the transfer and dematerialisation of physical shares. This initiative aligns with SEBI's circular dated January 30, 2026. The information was published on May 20, 2026, in Business Standard and Sakal.
Read the summary - Medium impact
Sanofi India Limited Appoints Rahul Bhatnagar as Chairman of Board of Directors
Sanofi India Limited appointed Rahul Bhatnagar as Chairman of the Board of Directors, effective April 30, 2026. He succeeds Aditya Narayan. Bhatnagar is a Chartered Accountant and Wharton MBA with extensive leadership experience.
Read the summary - Medium impact
Sanofi India Limited Holds 70th AGM, Approves Financials & Dividends
Sanofi India Limited held its 70th AGM on April 29, 2026. Shareholders approved the annual audited financial statements for FY 2025 and a final dividend of ₹48 per share, in addition to an interim dividend of ₹75 per share. Key appointments and related party transactions were also approved.
Read the summary - Medium impact
Sanofi India Limited's 70th AGM: All resolutions passed, including dividend and director appointments.
Sanofi India Limited's 70th AGM on April 29, 2026, saw all resolutions passed. Key approvals include the FY25 financial statements, an interim dividend of ₹75 and final dividend of ₹48 per share. Directors Vaibhav Karandikar, Eric Mansion, Sudipta Chakraborty, Rajani Kesari, and Siraj Azmat Chaudhry were appointed or re-appointed. Related party transactions were also approved.
Read the summary - Low impact
Sanofi India Announces Newspaper Publication of Q1 2026 Financial Results
Sanofi India Limited published its financial results for the quarter ended March 31, 2026, on April 29, 2026. The publication was made in Business Standard (English) and Sakal (Marathi) as per SEBI regulations.
Read the summary - Medium impact
Sanofi India Board Approves Q1 2026 Results; New Chairman Appointed
Sanofi India Limited approved its Q1 2026 Unaudited Financial Results. The company's Insulin portfolio showed strong domestic growth. Mr. Rahul Bhatnagar was appointed Chairman of the Board effective April 30, 2026. Independent Directors Mr. Aditya Narayan and Mrs. Usha Thorat completed their tenures on April 29, 2026.
Read the summary - Medium impact
Sanofi India Board Meeting Outcome: Approves Q1 2026 Results, Appoints New Chairman
Sanofi India's Board approved Q1 2026 results. Independent Directors Mr. Aditya Narayan and Mrs. Usha Thorat's tenure ends April 29, 2026. Mr. Rahul Bhatnagar appointed new Chairman from April 30, 2026. Committees reconstituted. Insulin portfolio showed double-digit growth.
Read the summary - Medium impact
Sanofi India Board Approves Q1 2026 Results; Key Director Changes Announced
Sanofi India Limited reported Q1 2026 results with profit after tax of ₹1,026 million. Revenue from operations was ₹4,723 million. The insulin portfolio showed strong double-digit growth. Mr. Rahul Bhatnagar was appointed Chairman of the Board, effective April 30, 2026. Independent Directors Mr. Aditya Narayan and Mrs. Usha Thorat completed their tenures on April 29, 2026.
Read the summary - Medium impact
Sanofi India Board Approves Q1 2026 Results; Key Director Changes Announced
Sanofi India Limited approved its unaudited financial results for the quarter ended March 31, 2026. The Board noted the completion of tenure for two Independent Directors and appointed Mr. Rahul Bhatnagar as Chairman of the Board, effective April 30, 2026. The company reported strong growth in its insulin portfolio.
Read the summary - Low impact
Sanofi India Gets GST Refund Order of ₹52 Lakhs, Appeals for ₹11.6 Lakhs
Sanofi India received a GST refund order of ₹52.08 Lakhs, comprising ₹33.97 Lakhs principal and ₹18.11 Lakhs interest, for the period August 2014 to June 2017. The company will appeal for the un-granted ₹11.63 Lakhs of its ₹45.60 Lakhs claim.
Read the summary - Low impact
Sanofi India Limited files SEBI Regulation 74(5) Certificate for period ended March 31, 2026
Sanofi India Limited has filed a certificate under SEBI Regulation 74(5) for the period ending March 31, 2026. The RTA, MUFG Intime India Private Limited, confirmed the processing of dematerialised securities. This is a routine compliance filing.
Read the summary - Low impact
Sanofi India Limited Announces 70th AGM, Dividend, and Integrated Annual Report Publication
Sanofi India Limited announced its 70th AGM details, including the Integrated Annual Report and e-voting information. The company also published details about the final dividend and 'Saksham Niveshak'. Newspaper advertisements were released on April 3, 2026.
Read the summary - Medium impact
Sanofi India Limited Announces 70th AGM on April 29, 2026, with ₹48 Dividend
Sanofi India Limited will hold its 70th AGM on April 29, 2026, via VC/OAVM. A final dividend of ₹48 per share will be paid on or before May 28, 2026. The record date for the dividend is April 22, 2026. The company is also facilitating KYC updates and a special window for physical security dematerialization.
Read the summary - Medium impact
Sanofi India Recommends Final Dividend of ₹48/Share; Sets Record Date for April 22
Sanofi India recommended a final dividend of ₹48 per equity share for FY25, subject to shareholder approval at the AGM. The record date for dividend eligibility is April 22, 2026. Shareholders must update their details by this date for TDS compliance. Physical dividend warrants will be discontinued from November 19, 2025.
Read the summary - Medium impact
Sanofi India: Central Govt Approves Deepak Arora's MD Appointment for 3 Years
Sanofi India Limited announced the Central Government's approval for Mr. Deepak Arora's appointment as Managing Director for three years, effective October 27, 2025. The approval letter was received on April 1, 2026. This follows earlier intimations on October 27 and December 18, 2025.
Read the summary - Low impact
Sanofi India Ltd. Releases Business Responsibility and Sustainability Report for FY2025
Sanofi India Limited has released its Business Responsibility and Sustainability Report for the financial year ended December 31, 2025. The report details the company's ESG initiatives, including emission reduction targets, renewable energy goals, and employee well-being programs, showcasing its commitment to sustainable and ethical business practices.
Read the summary - Medium impact
Sanofi India Announces 70th AGM on April 29, 2026, to Discuss Financials and Board Appointments
Sanofi India Limited will hold its 70th AGM on April 29, 2026. The meeting will discuss the financial year 2025 results and dividends. Key agenda items include appointing Ms. Sudipta Chakraborty as Whole-time Director and Mrs. Rajani Kesari and Mr. Siraj Azmat Chaudhry as Independent Directors. Approvals for related-party transactions up to ₹13,850 million and ₹5,300 million are also on the agenda.
Read the summary - Low impact
Sanofi India Limited Announces 70th AGM on April 29, 2026, and Dividend Record Date
Sanofi India Limited will hold its 70th Annual General Meeting on April 29, 2026, at 3:30 p.m. IST via video conference. The company also announced the record date for its final dividend and a special window for physical share transfer re-lodgement.
Read the summary - Medium impact
Sanofi India Limited receives ₹12.37 Crore tax order for FY23
Sanofi India Limited received a final tax assessment order for FY 2022-23 from the Income Tax Department. The order includes a tax liability of ₹12.37 crore, including interest, due to transfer pricing adjustments and disallowances. The company plans to appeal the order.
Read the summary - Medium impact
Sanofi India Board Approves 70th AGM, Final Dividend, and Appoints New Independent Director
Sanofi India's Board approved convening the 70th AGM on April 29, 2026. A final dividend of ₹48 per share for FY2025 was recommended, with the record date set for April 22, 2026. Mr. Siraj Azmat Chaudhry was appointed as an Additional and Independent Director for a five-year term starting April 1, 2026.
Read the summary - Medium impact
Sanofi India Board Approves 70th AGM, Appoints New Independent Director
Sanofi India's Board approved the 70th AGM on April 29, 2026. A Final Dividend of ₹48 per equity share was recommended for FY2025. The record date is April 22, 2026. Mr. Siraj Azmat Chaudhry was appointed as an Additional and Independent Director for five years from April 1, 2026.
Read the summary - Medium impact
Sanofi India Board Approves 70th AGM, Final Dividend, and New Independent Director Appointment
Sanofi India's Board approved the 70th AGM on April 29, 2026, and a final dividend of ₹48 per share for FY25. Mr. Siraj Azmat Chaudhry was appointed as an Additional Director and Independent Director for five years from April 1, 2026. Record date for dividend is April 22, 2026.
Read the summary - Medium impact
Sanofi India Board Approves 70th AGM, Final Dividend & Appoints Siraj Chaudhry as Independent Director
Sanofi India's Board approved the 70th AGM on April 29, 2026. A final dividend of ₹48 per share was recommended for FY25. Mr. Siraj Azmat Chaudhry was appointed as an Additional and Independent Director for a five-year term from April 1, 2026.
Read the summary - Low impact
Sanofi India Trading Window Closed for Q4 FY26 Results from Apr 1
Sanofi India Limited will close its trading window from April 1, 2026. The closure is for the declaration of financial results for the quarter ending March 31, 2026. The window will reopen 48 hours after the results are announced.
Read the summary - Low impact
Sanofi India to Meet Analysts/Institutional Investors on April 1, 2026
Sanofi India Limited officials will meet with an Analyst/Institutional Investor on April 1, 2026, in Mumbai. Discussions will be limited to publicly available information, with no UPSI disclosure. The schedule is subject to change.
Read the summary - Low impact
Sanofi India Limited Issues Notice to Shareholders for IEPF Fund Transfer
Sanofi India Limited is notifying shareholders about the potential transfer of their shares to the IEPF. This is for shareholders who haven't claimed dividends for seven or more consecutive years, as per company law.
Read the summary - Medium impact
Sanofi India Releases Transcript of Investor/Analyst Call for Q4 & FY25 Results
Sanofi India released the transcript of its investor call for Q4 and FY25 results. The company is transforming its business model for sustainable growth, focusing on diabetes and insulin. Despite flat domestic sales in 2025, profit before tax increased by 1%. Lantus and Toujeo showed strong performance in the diabetes segment. Partnership sales experienced fluctuations due to stock movements, but the underlying business is growing. A dividend increase of 5% is proposed.
Read the summary - Low impact
Sanofi India: Video Recording of Investor Call on Q4 FY25 Results Available Online
Sanofi India Limited has uploaded the video recording of its investor and analyst call. The call, held on February 26, 2026, discussed the financial results for the quarter and year ended December 31, 2025. The recording is available on the company's website.
Read the summary - Low impact
Sanofi India Limited Publishes Financial Results for Q4 and FY Ended December 31, 2025
Sanofi India Limited published its financial results for the quarter and year ended December 31, 2025. The results were published on February 26, 2026, in Business Standard and Sakal newspapers.
Read the summary - Medium impact
Sanofi India Investor Presentation: Focus on Diabetes, Business Model Transformation
Sanofi India Limited's investor presentation reveals a business model transformation focusing on sustainable growth in diabetes. Domestic sales were flat in 2025, but PBT rose 1%. The company is enhancing its Insulin franchise and partnership model. Net sales for FY25 increased 1% to ₹15,115 million, and PBT grew 1% to ₹4,720 million. A dividend of ₹158 per share is proposed.
Read the summary - Medium impact
Sanofi India Board Approves Audited FY25 Results, Final Dividend of ₹48, Appoints Additional Directors
Sanofi India's board approved audited FY25 results and recommended a final dividend of ₹48 per share, in addition to the ₹75 interim dividend. Mrs. Rajani Kesari was appointed as an Additional and Independent Director effective 1st April 2026, while Ms. Sudipta Chakraborty was appointed as an Additional and Whole-time Director from 1st March 2026. Mr. Rodolfo Hrosz resigned as Non-Executive Director, effective 28th February 2026.
Read the summary - Medium impact
Sanofi India FY25: Final Dividend ₹48/Share, Rajani Kesari & Sudipta Chakraborty Appointed as Directors
Sanofi India's board approved audited FY25 results and recommended a final dividend of ₹48 per share, in addition to the ₹75 interim dividend. Rajani Kesari was appointed as an Additional and Independent Director for 5 years starting 1st April 2026. Sudipta Chakraborty was appointed as an Additional and Whole-time Director for 3 years starting 1st March 2026. Rodolfo Hrosz resigned as Non-Executive Director effective 28th February 2026.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio